Chapter 1 The Function, Proteolytic Processing, and Histopathology of Met in Cancer

Advances in Cancer Research

Volumn 103, Issue C, 2009, Pages 1-23

  Hanna, Jason A ^a   Bordeaux, Jennifer ^a   Rimm, David L ^a   Agarwal, Seema ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 102; CANNABINOID 1 RECEPTOR; CASPASE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DN30; PROTEIN P40; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; XL 184; ANTINEOPLASTIC AGENT; GROWTH FACTOR RECEPTOR; MET PROTEIN, HUMAN; ONCOPROTEIN;

BREAST TUMOR; CANCER THERAPY; CELL NUCLEUS; CELLULAR DISTRIBUTION; CLINICAL TRIAL; COLON CANCER; DRUG TARGETING; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; KIDNEY CANCER; LIVER CELL CARCINOMA; LUNG CANCER; MELANOMA; NEOPLASM; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REVIEW; STOMACH CANCER; STOMACH CARCINOMA; UBIQUITINATION; ANIMAL; BIOLOGICAL MODEL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; SYNTHESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL NUCLEUS; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS; RECEPTOR CROSS-TALK; RECEPTORS, GROWTH FACTOR;

EID: 71149106650     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-230X(09)03001-2     Document Type: Review

References (121)

1. Abella J.V., Peschard P., Naujokas M.A., Lin T., Saucier C., Urbe S., and Park M. Met/hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation. Mol. Cell Biol. 25 (2005) 9632-9645
2. Agarwal S., Zerillo C., Kolmakova J., Christensen J.G., Harris L.N., Rimm D.L., Digiovanna M.P., and Stern D.F. Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells. Br. J. Cancer 100 (2009) 941-949
3. Amemiya H., Kono K., Itakura J., Tang R.F., Takahashi A., An F.Q., Kamei S., Iizuka H., Fujii H., and Matsumoto Y. c-Met expression in gastric cancer with liver metastasis. Oncology 63 (2002) 286-296
4. Athauda G., Giubellino A., Coleman J.A., Horak C., Steeg P.S., Lee M.J., Trepel J., Wimberly J., Sun J., Coxon A., Burgess T.L., and Bottaro D.P. c-Met ectodomain shedding rate correlates with malignant potential. Clin. Cancer Res. 12 (2006) 4154-4162
5. Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L., Chitale D., Motoi N., Szoke J., Broderick S., Balak M., Chang W.C., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl. Acad. Sci. USA 104 (2007) 20932-20937
6. Bertotti A., Comoglio P.M., and Trusolino L. Beta4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis. Cancer Res. 65 (2005) 10674-10679
7. Bertotti A., Comoglio P.M., and Trusolino L. Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth. J. Cell Biol. 175 (2006) 993-1003
8. Beuret L., Flori E., Denoyelle C., Bille K., Busca R., Picardo M., Bertolotto C., and Ballotti R. Up-regulation of MET expression by alpha-melanocyte-stimulating hormone and MITF allows hepatocyte growth factor to protect melanocytes and melanoma cells from apoptosis. J. Biol. Chem. 282 (2007) 14140-14147
9. Bharti A., Ma P.C., Maulik G., Singh R., Khan E., Skarin A.T., and Salgia R. Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer. Anticancer Res. 24 (2004) 1031-1038
10. Birchmeier C., Birchmeier W., Gherardi E., and Vande Woude G.F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 4 (2003) 915-925
11. Bladt F., Riethmacher D., Isenmann S., Aguzzi A., and Birchmeier C. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 376 (1995) 768-771
12. Borowiak M., Garratt A.N., Wustefeld T., Strehle M., Trautwein C., and Birchmeier C. Met provides essential signals for liver regeneration. Proc. Natl. Acad. Sci. USA 101 (2004) 10608-10613
13. Brown M.S., Ye J., Rawson R.B., and Goldstein J.L. Regulated intramembrane proteolysis: A control mechanism conserved from bacteria to humans. Cell 100 (2000) 391-398
14. Burgess T., Coxon A., Meyer S., Sun J., Rex K., Tsuruda T., Chen Q., Ho S.Y., Li L., Kaufman S., McDorman K., Cattley R.C., et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res. 66 (2006) 1721-1729
15. Cappuzzo F., Janne P.A., Skokan M., Finocchiaro G., Rossi E., Ligorio C., Zucali P.A., Terracciano L., Toschi L., Roncalli M., Destro A., Incarbone M., et al. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann. Oncol. 20 (2009) 298-304
16. Cappuzzo F., Marchetti A., Skokan M., Rossi E., Gajapathy S., Felicioni L., Del Grammastro M., Sciarrotta M.G., Buttitta F., Incarbone M., Toschi L., Finocchiaro G., et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J. Clin. Oncol. 27 (2009) 1667-1674
17. Carpenter G., and Liao H.J. Trafficking of receptor tyrosine kinases to the nucleus. Exp. Cell Res. 315 (2009) 1556-1566
18. Cheng H.L., Liu H.S., Lin Y.J., Chen H.H., Hsu P.Y., Chang T.Y., Ho C.L., Tzai T.S., and Chow N.H. Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. Br. J. Cancer 92 (2005) 1906-1914
19. Chmielowiec J., Borowiak M., Morkel M., Stradal T., Munz B., Werner S., Wehland J., Birchmeier C., and Birchmeier W. c-Met is essential for wound healing in the skin. J. Cell Biol. 177 (2007) 151-162
20. Comoglio P.M., Giordano S., and Trusolino L. Drug development of MET inhibitors: Targeting oncogene addiction and expedience. Nat. Rev. Drug Discov. 7 (2008) 504-516
21. Conrotto P., Corso S., Gamberini S., Comoglio P.M., and Giordano S. Interplay between scatter factor receptors and B plexins controls invasive growth. Oncogene 23 (2004) 5131-5137
22. Conrotto P., Valdembri D., Corso S., Serini G., Tamagnone L., Comoglio P.M., Bussolino F., and Giordano S. Sema4D induces angiogenesis through Met recruitment by Plexin B1. Blood 105 (2005) 4321-4329
23. Cruz J., Reis-Filho J.S., Silva P., and Lopes J.M. Expression of c-met tyrosine kinase receptor is biologically and prognostically relevant for primary cutaneous malignant melanomas. Oncology 65 (2003) 72-82
24. Danilkovitch-Miagkova A., and Zbar B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J. Clin. Invest. 109 (2002) 863-867
25. Deheuninck J., Foveau B., Goormachtigh G., Leroy C., Ji Z., Tulasne D., and Fafeur V. Caspase cleavage of the MET receptor generates an HGF interfering fragment. Biochem. Biophys. Res. Commun. 367 (2008) 573-577
26. Edakuni G., Sasatomi E., Satoh T., Tokunaga O., and Miyazaki K. Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma. Pathol. Int. 51 (2001) 172-178
27. Eder J.P., Vande Woude G.F., Boerner S.A., and LoRusso P.M. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin. Cancer Res. 15 (2009) 2207-2214
28. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., Lindeman N., Gale C.M., Zhao X., Christensen J., Kosaka T., Holmes A.J., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316 (2007) 1039-1043
29. Fischer O.M., Giordano S., Comoglio P.M., and Ullrich A. Reactive oxygen species mediate Met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells. J. Biol. Chem. 279 (2004) 28970-28978
30. Follenzi A., Bakovic S., Gual P., Stella M.C., Longati P., and Comoglio P.M. Cross-talk between the proto-oncogenes Met and Ron. Oncogene 19 (2000) 3041-3049
31. Foveau B., Leroy C., Ancot F., Deheuninck J., Ji Z., Fafeur V., and Tulasne D. Amplification of apoptosis through sequential caspase cleavage of the MET tyrosine kinase receptor. Cell Death Differ. 14 (2007) 752-764
32. Foveau B., Ancot F., Leroy C., Petrelli A., Reiss K., Vingtdeux V., Giordano S., Fafeur V., and Tulasne D. Downregulation of the Met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis. Mol. Biol. Cell 20 (2009) 2495-2507
33. Gentile A., Trusolino L., and Comoglio P.M. The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev. 27 (2008) 85-94
34. Gherardi E., Love C.A., Esnouf R.M., and Jones E.Y. The sema domain. Curr. Opin. Struct. Biol. 14 (2004) 669-678
35. Ginty F., Adak S., Can A., Gerdes M., Larsen M., Cline H., Filkins R., Pang Z., Li Q., and Montalto M.C. The relative distribution of membranous and cytoplasmic met is a prognostic indicator in stage I and II colon cancer. Clin. Cancer Res. 14 (2008) 3814-3822
36. Giordano S., Corso S., Conrotto P., Artigiani S., Gilestro G., Barberis D., Tamagnone L., and Comoglio P.M. The semaphorin 4D receptor controls invasive growth by coupling with Met. Nat. Cell Biol. 4 (2002) 720-724
37. Gomes D.A., Rodrigues M.A., Leite M.F., Gomez M.V., Varnai P., Balla T., Bennett A.M., and Nathanson M.H. c-Met must translocate to the nucleus to initiate calcium signals. J. Biol. Chem. 283 (2008) 4344-4351
38. Guo A., Villen J., Kornhauser J., Lee K.A., Stokes M.P., Rikova K., Possemato A., Nardone J., Innocenti G., Wetzel R., Wang Y., MacNeill J., et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc. Natl. Acad. Sci. USA 105 (2008) 692-697
39. Hara T., Ooi A., Kobayashi M., Mai M., Yanagihara K., and Nakanishi I. Amplification of c-myc, K-sam, and c-met in gastric cancers: Detection by fluorescence in situ hybridization. Lab. Invest. 78 (1998) 1143-1153
40. Hiscox S., and Jiang W.G. Association of the HGF/SF receptor, c-met, with the cell-surface adhesion molecule, E-cadherin, and catenins in human tumor cells. Biochem. Biophys. Res. Commun. 261 (1999) 406-411
41. Hu B., Guo P., Bar-Joseph I., Imanishi Y., Jarzynka M.J., Bogler O., Mikkelsen T., Hirose T., Nishikawa R., and Cheng S.Y. Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway. Oncogene 26 (2007) 5577-5586
42. Humphrey P.A., Zhu X., Zarnegar R., Swanson P.E., Ratliff T.L., Vollmer R.T., and Day M.L. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am. J. Pathol. 147 (1995) 386-396
43. Ichimura E., Maeshima A., Nakajima T., and Nakamura T. Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn. J. Cancer Res. 87 (1996) 1063-1069
44. Jagadeeswaran R., Ma P.C., Seiwert T.Y., Jagadeeswaran S., Zumba O., Nallasura V., Ahmed S., Filiberti R., Paganuzzi M., Puntoni R., Kratzke R.A., Gordon G.J., et al. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res. 66 (2006) 352-361
45. Jeffers M., Taylor G.A., Weidner K.M., Omura S., and Vande Woude G.F. Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway. Mol. Cell Biol. 17 (1997) 799-808
46. Jin L., Fuchs A., Schnitt S.J., Yao Y., Joseph A., Lamszus K., Park M., Goldberg I.D., and Rosen E.M. Expression of scatter factor and c-met receptor in benign and malignant breast tissue. Cancer 79 (1997) 749-760
47. Jo M., Stolz D.B., Esplen J.E., Dorko K., Michalopoulos G.K., and Strom S.C. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J. Biol. Chem. 275 (2000) 8806-8811
48. Kammula U.S., Kuntz E.J., Francone T.D., Zeng Z., Shia J., Landmann R.G., Paty P.B., and Weiser M.R. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett. 248 (2007) 219-228
49. Kang J.Y., Dolled-Filhart M., Ocal I.T., Singh B., Lin C.Y., Dickson R.B., Rimm D.L., and Camp R.L. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res. 63 (2003) 1101-1105
50. Kanteti R., Nallasura V., Loganathan S., Tretiakova M., Kroll T., Krishnaswamy S., Faoro L., Cagle P., Husain A.N., Vokes E.E., Lang D., and Salgia R. PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. Lab. Invest. 89 (2009) 301-314
51. Ke A.W., Shi G.M., Zhou J., Wu F.Z., Ding Z.B., Hu M.Y., Xu Y., Song Z.J., Wang Z.J., Wu J.C., Bai D.S., Li J.C., et al. Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology 49 (2009) 491-503
52. Knudsen B.S., and Edlund M. Prostate cancer and the met hepatocyte growth factor receptor. Adv. Cancer Res. 91 (2004) 31-67
53. Knudsen B.S., Gmyrek G.A., Inra J., Scherr D.S., Vaughan E.D., Nanus D.M., Kattan M.W., Gerald W.L., and Vande Woude G.F. High expression of the Met receptor in prostate cancer metastasis to bone. Urology 60 (2002) 1113-1117
54. Knudsen B.S., Zhao P., Resau J., Cottingham S., Gherardi E., Xu E., Berghuis B., Daugherty J., Grabinski T., Toro J., Giambernardi T., Skinner R.S., et al. A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings. Appl. Immunohistochem. Mol. Morphol. 17 (2009) 57-67
55. Koochekpour S., Jeffers M., Rulong S., Taylor G., Klineberg E., Hudson E.A., Resau J.H., and Vande Woude G.F. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res. 57 (1997) 5391-5398
56. Kopitz C., Gerg M., Bandapalli O.R., Ister D., Pennington C.J., Hauser S., Flechsig C., Krell H.W., Antolovic D., Brew K., Nagase H., Stangl M., et al. Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. Cancer Res. 67 (2007) 8615-8623
57. Lee J.H., Han S.U., Cho H., Jennings B., Gerrard B., Dean M., Schmidt L., Zbar B., and Vande Woude G.F. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 19 (2000) 4947-4953
58. Lee W.Y., Chen H.H., Chow N.H., Su W.C., Lin P.W., and Guo H.R. Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients. Clin. Cancer Res. 11 (2005) 2222-2228
59. Lee C.T., Chow N.H., Su P.F., Lin S.C., Lin P.C., and Lee J.C. The prognostic significance of RON and MET receptor coexpression in patients with colorectal cancer. Dis. Colon Rectum 51 (2008) 1268-1274
60. Ma P.C., Kijima T., Maulik G., Fox E.A., Sattler M., Griffin J.D., Johnson B.E., and Salgia R. c-MET mutational analysis in small cell lung cancer: Novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 63 (2003) 6272-6281
61. Ma P.C., Jagadeeswaran R., Jagadeesh S., Tretiakova M.S., Nallasura V., Fox E.A., Hansen M., Schaefer E., Naoki K., Lader A., Richards W., Sugarbaker D., et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 65 (2005) 1479-1488
62. Ma P.C., Tretiakova M.S., Nallasura V., Jagadeeswaran R., Husain A.N., and Salgia R. Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: Implications for tumour invasion. Br. J. Cancer 97 (2007) 368-377
63. Maggiora P., Lorenzato A., Fracchioli S., Costa B., Castagnaro M., Arisio R., Katsaros D., Massobrio M., Comoglio P.M., and Flavia Di Renzo M. The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Exp. Cell Res. 288 (2003) 382-389
64. Mak H.H., Peschard P., Lin T., Naujokas M.A., Zuo D., and Park M. Oncogenic activation of the Met receptor tyrosine kinase fusion protein, Tpr-Met, involves exclusion from the endocytic degradative pathway. Oncogene 26 (2007) 7213-7221
65. Mallikarjuna K., Pushparaj V., Biswas J., and Krishnakumar S. Expression of epidermal growth factor receptor, ezrin, hepatocyte growth factor, and c-Met in uveal melanoma: An immunohistochemical study. Curr. Eye Res. 32 (2007) 281-290
66. Martens T., Schmidt N.O., Eckerich C., Fillbrandt R., Merchant M., Schwall R., Westphal M., and Lamszus K. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin. Cancer Res. 12 (2006) 6144-6152
67. Masuya D., Huang C., Liu D., Nakashima T., Kameyama K., Haba R., Ueno M., and Yokomise H. The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients. Br. J. Cancer 90 (2004) 1555-1562
68. Matteucci E., Bendinelli P., and Desiderio M.A. Nuclear localization of active HGF receptor Met in aggressive MDA-MB231 breast carcinoma cells. Carcinogenesis 30 (2009) 937-945
69. McGill G.G., Haq R., Nishimura E.K., and Fisher D.E. c-Met expression is regulated by Mitf in the melanocyte lineage. J. Biol. Chem. 281 (2006) 10365-10373
70. Merlin S., Pietronave S., Locarno D., Valente G., Follenzi A., and Prat M. Deletion of the ectodomain unleashes the transforming, invasive, and tumorigenic potential of the MET oncogene. Cancer Sci. 100 (2009) 633-638
71. Michieli P., Mazzone M., Basilico C., Cavassa S., Sottile A., Naldini L., and Comoglio P.M. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 6 (2004) 61-73
72. Moon Y.W., Weil R.J., Pack S.D., Park W.S., Pak E., Pham T., Karkera J.D., Kim H.K., Vortmeyer A.O., Fuller B.G., and Zhuang Z. Missense mutation of the MET gene detected in human glioma. Mod. Pathol. 13 (2000) 973-977
73. Moore S.R., Persons D.L., Sosman J.A., Bobadilla D., Bedell V., Smith D.D., Wolman S.R., Tuthill R.J., Moon J., Sondak V.K., and Slovak M.L. Detection of copy number alterations in metastatic melanoma by a DNA fluorescence in situ hybridization probe panel and array comparative genomic hybridization: A southwest oncology group study (S9431). Clin. Cancer Res. 14 (2008) 2927-2935
74. Mueller K.L., Hunter L.A., Ethier S.P., and Boerner J.L. Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. Cancer Res. 68 (2008) 3314-3322
75. Nabeshima K., Shimao Y., Sato S., Kataoka H., Moriyama T., Kawano H., Wakisaka S., and Koono M. Expression of c-Met correlates with grade of malignancy in human astrocytic tumours: An immunohistochemical study. Histopathology 31 (1997) 436-443
76. Nakamura Y., Niki T., Goto A., Morikawa T., Miyazawa K., Nakajima J., and Fukayama M. c-Met activation in lung adenocarcinoma tissues: An immunohistochemical analysis. Cancer Sci. 98 (2007) 1006-1013
77. Natali P.G., Nicotra M.R., Di Renzo M.F., Prat M., Bigotti A., Cavaliere R., and Comoglio P.M. Expression of the c-Met/HGF receptor in human melanocytic neoplasms: Demonstration of the relationship to malignant melanoma tumour progression. Br. J. Cancer 68 (1993) 746-750
78. Nath D., Williamson N.J., Jarvis R., and Murphy G. Shedding of c-Met is regulated by crosstalk between a G-protein coupled receptor and the EGF receptor and is mediated by a TIMP-3 sensitive metalloproteinase. J. Cell Sci. 114 (2001) 1213-1220
79. Niranjan B., Buluwela L., Yant J., Perusinghe N., Atherton A., Phippard D., Dale T., Gusterson B., and Kamalati T. HGF/SF: A potent cytokine for mammary growth, morphogenesis and development. Development 121 (1995) 2897-2908
80. Nishi N., Oya H., Matsumoto K., Nakamura T., Miyanaka H., and Wada F. Changes in gene expression of growth factors and their receptors during castration-induced involution and androgen-induced regrowth of rat prostates. Prostate 28 (1996) 139-152
81. Ohmichi H., Koshimizu U., Matsumoto K., and Nakamura T. Hepatocyte growth factor (HGF) acts as a mesenchyme-derived morphogenic factor during fetal lung development. Development 125 (1998) 1315-1324
82. Okuda K., Sasaki H., Yukiue H., Yano M., and Fujii Y. Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci. 99 (2008) 2280-2285
83. Orian-Rousseau V., Chen L., Sleeman J.P., Herrlich P., and Ponta H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev. 16 (2002) 3074-3086
84. Orian-Rousseau V., Morrison H., Matzke A., Kastilan T., Pace G., Herrlich P., and Ponta H. Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin. Mol. Biol. Cell 18 (2007) 76-83
85. Park M., Dean M., Cooper C.S., Schmidt M., O'Brien S.J., Blair D.G., and Vande Woude G.F. Mechanism of met oncogene activation. Cell 45 (1986) 895-904
86. Peschard P., Fournier T.M., Lamorte L., Naujokas M.A., Band H., Langdon W.Y., and Park M. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol. Cell 8 (2001) 995-1004
87. Peschard P., Ishiyama N., Lin T., Lipkowitz S., and Park M. A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation. J. Biol. Chem. 279 (2004) 29565-29571
88. Petrelli A., Gilestro G.F., Lanzardo S., Comoglio P.M., Migone N., and Giordano S. The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met. Nature 416 (2002) 187-190
89. Petrelli A., Circosta P., Granziero L., Mazzone M., Pisacane A., Fenoglio S., Comoglio P.M., and Giordano S. Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc. Natl. Acad. Sci. USA 103 (2006) 5090-5095
90. Pisters L.L., Troncoso P., Zhau H.E., Li W., von Eschenbach A.C., and Chung L.W. c-Met proto-oncogene expression in benign and malignant human prostate tissues. J. Urol. 154 (1995) 293-298
91. Pozner-Moulis S., Pappas D.J., and Rimm D.L. Met, the hepatocyte growth factor receptor, localizes to the nucleus in cells at low density. Cancer Res. 66 (2006) 7976-7982
92. Pozner-Moulis S., Cregger M., Camp R.L., and Rimm D.L. Antibody validation by quantitative analysis of protein expression using expression of Met in breast cancer as a model. Lab. Invest. J. Tech. Methods Pathol. 87 (2007) 251-260
93. Prat M., Crepaldi T., Pennacchietti S., Bussolino F., and Comoglio P.M. Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. J. Cell Sci. 111 Pt 2 (1998) 237-247
94. Puri N., Ahmed S., Janamanchi V., Tretiakova M., Zumba O., Krausz T., Jagadeeswaran R., and Salgia R. c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin. Cancer Res. 13 (2007) 2246-2253
95. Reardon D.A., Cloughsey T.F., Raizer J.J., Laterra J., Schiff D., Yang X., Loh E., and Wen P.Y. Phase II study of AMG 102, a fully human neutralizing antibody against hepatocyte growth factor/scatter factor, in patients with recurrent glioblastoma multiforme. 2008 ASCO Annual Meeting Proceedings. Journal of Clinical Oncology Vol. 26 (2008)
96. Reshetnikova G., Troyanovsky S., and Rimm D.L. Definition of a direct extracellular interaction between Met and E-cadherin. Cell Biol. Int. 31 (2007) 366-373
97. Saitoh K., Takahashi H., Sawada N., and Parsons P.G. Detection of the c-met proto-oncogene product in normal skin and tumours of melanocytic origin. J. Pathol. 174 (1994) 191-199
98. Salgia R., Peterson A., Eppler S., Yu W., Polite B., Geary D., Wesolowski E., LaRosiliere M., Ratain M., and Sovak M. A phase I, open-label, dose-escalation study of the safety and pharmacology of MetMAb, a monovalent antagonist antibody to the receptor c-Met, administered IV in patients with locally advanced or metastatic solid tumors. 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Geneva, Switzerland (2008)
99. Schmidt C., Bladt F., Goedecke S., Brinkmann V., Zschiesche W., Sharpe M., Gherardi E., and Birchmeier C. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 373 (1995) 699-702
100. Shattuck D.L., Miller J.K., Carraway III K.L., and Sweeney C. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res. 68 (2008) 1471-1477
101. Smolen G.A., Sordella R., Muir B., Mohapatra G., Barmettler A., Archibald H., Kim W.J., Okimoto R.A., Bell D.W., Sgroi D.C., Christensen J.C., Settleman J., et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc. Natl. Acad. Sci. USA 103 (2006) 2316-2321
102. Soman N.R., Correa P., Ruiz B.A., and Wogan G.N. The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions. Proc. Natl. Acad. Sci. USA 88 (1991) 4892-4896
103. Takanami I., Tanana F., Hashizume T., Kikuchi K., Yamamoto Y., Yamamoto T., and Kodaira S. Hepatocyte growth factor and c-Met/hepatocyte growth factor receptor in pulmonary adenocarcinomas: An evaluation of their expression as prognostic markers. Oncology 53 (1996) 392-397
104. Takeuchi H., Bilchik A., Saha S., Turner R., Wiese D., Tanaka M., Kuo C., Wang H.J., and Hoon D.S. c-MET expression level in primary colon cancer: A predictor of tumor invasion and lymph node metastases. Clin. Cancer Res. 9 (2003) 1480-1488
105. Tang Z., Du R., Jiang S., Wu C., Barkauskas D.S., Richey J., Molter J., Lam M., Flask C., Gerson S., Dowlati A., Liu L., et al. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br. J. Cancer 99 (2008) 911-922
106. Taniguchi K., Yonemura Y., Nojima N., Hirono Y., Fushida S., Fujimura T., Miwa K., Endo Y., Yamamoto H., and Watanabe H. The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor. Cancer 82 (1998) 2112-2122
107. TCGA Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455 (2008) 1061-1068
108. Thomas R.M., Toney K., Fenoglio-Preiser C., Revelo-Penafiel M.P., Hingorani S.R., Tuveson D.A., Waltz S.E., and Lowy A.M. The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Res. 67 (2007) 6075-6082
109. Tolgay Ocal I., Dolled-Filhart M., D'Aquila T.G., Camp R.L., and Rimm D.L. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Cancer 97 (2003) 1841-1848
110. Trusolino L., Bertotti A., and Comoglio P.M. A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. Cell 107 (2001) 643-654
111. Tsao M.S., Liu N., Chen J.R., Pappas J., Ho J., To C., Viallet J., Park M., and Zhu H. Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers. Lung Cancer 20 (1998) 1-16
112. Tsarfaty I., Alvord W.G., Resau J.H., Altstock R.T., Lidereau R., Bieche I., Bertrand F., Horev J., Klabansky R.L., Keydar I., and Vande Woude G.F. Alteration of Met protooncogene product expression and prognosis in breast carcinomas. Anal. Quant. Cytol. Histol. 21 (1999) 397-408
113. Tuck A.B., Park M., Sterns E.E., Boag A., and Elliott B.E. Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. Am. J. Pathol. 148 (1996) 225-232
114. Tulasne D., and Foveau B. The shadow of death on the MET tyrosine kinase receptor. Cell Death Differ. 15 (2008) 427-434
115. Tulasne D., Deheuninck J., Lourenco F.C., Lamballe F., Ji Z., Leroy C., Puchois E., Moumen A., Maina F., Mehlen P., and Fafeur V. Proapoptotic function of the MET tyrosine kinase receptor through caspase cleavage. Mol. Cell Biol. 24 (2004) 10328-10339
116. Ueki T., Fujimoto J., Suzuki T., Yamamoto H., and Okamoto E. Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology 25 (1997) 619-623
117. Verras M., Lee J., Xue H., Li T.H., Wang Y., and Sun Z. The androgen receptor negatively regulates the expression of c-Met: Implications for a novel mechanism of prostate cancer progression. Cancer Res. 67 (2007) 967-975
118. Wang X., DeFrances M.C., Dai Y., Pediaditakis P., Johnson C., Bell A., Michalopoulos G.K., and Zarnegar R. A mechanism of cell survival: Sequestration of Fas by the HGF receptor Met. Mol. Cell 9 (2002) 411-421
119. Watanabe M., Fukutome K., Kato H., Murata M., Kawamura J., Shiraishi T., and Yatani R. Progression-linked overexpression of c-Met in prostatic intraepithelial neoplasia and latent as well as clinical prostate cancers. Cancer Lett. 141 (1999) 173-178
120. Yano S., Wang W., Li Q., Matsumoto K., Sakurama H., Nakamura T., Ogino H., Kakiuchi S., Hanibuchi M., Nishioka Y., Uehara H., Mitsudomi T., et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 68 (2008) 9479-9487
121. Ye M., Hu D., Tu L., Zhou X., Lu F., Wen B., Wu W., Lin Y., Zhou Z., and Qu J. Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells. Invest. Ophthalmol. Vis. Sci. 49 (2008) 497-504